Prediction of Cisplatin-Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information

IF 3.1 3区 医学 Q2 MEDICINE, RESEARCH & EXPERIMENTAL Cts-Clinical and Translational Science Pub Date : 2025-01-06 DOI:10.1111/cts.70115
Kaori Ambe, Yuka Aoki, Miho Murashima, Chiharu Wachino, Yuto Deki, Masaya Ieda, Masahiro Kondo, Yoko Furukawa-Hibi, Kazunori Kimura, Takayuki Hamano, Masahiro Tohkin
{"title":"Prediction of Cisplatin-Induced Acute Kidney Injury Using an Interpretable Machine Learning Model and Electronic Medical Record Information","authors":"Kaori Ambe,&nbsp;Yuka Aoki,&nbsp;Miho Murashima,&nbsp;Chiharu Wachino,&nbsp;Yuto Deki,&nbsp;Masaya Ieda,&nbsp;Masahiro Kondo,&nbsp;Yoko Furukawa-Hibi,&nbsp;Kazunori Kimura,&nbsp;Takayuki Hamano,&nbsp;Masahiro Tohkin","doi":"10.1111/cts.70115","DOIUrl":null,"url":null,"abstract":"<p>Predicting cisplatin-induced acute kidney injury (Cis-AKI) before its onset is important. We aimed to develop a predictive model for Cis-AKI using patient clinical information based on an interpretable machine learning algorithm. This single-center retrospective study included hospitalized patients aged ≥ 18 years who received the first course of cisplatin chemotherapy from January 1, 2011, to December 31, 2020, at Nagoya City University Hospital. Cis-AKI-positive patients were defined using the serum creatinine criteria of the Kidney Disease Improving Global Outcomes guideline within 14 days of the last day of cisplatin administration in the first course. Patients who received cisplatin but did not develop AKI were considered negative. The CatBoost classification model was constructed with 29 explanatory variables, including laboratory values, concomitant medications, medical history, and cisplatin administration information. In total, 1253 patients were included, of whom 119 developed Cis-AKI (9.5%). The median time of AKI onset was 7 days, and the interquartile range was 5–8 days. The mean ± standard deviation of the total cisplatin dose in the initial treatment was 77.9 ± 27.1 mg/m<sup>2</sup> in Cis-AKI-positive patients and 69.3 ± 22.6 mg/m<sup>2</sup> in Cis-AKI-negative patients. The predictive performance was an ROC-AUC of 0.78. Model interpretation using SHapley Additive exPlanations showed that concomitant use of intravenous magnesium preparations was negatively correlated with Cis-AKI, whereas loop diuretics were positively correlated. This suggests the need for magnesium preparations to prevent AKI, although the effects of diuretics may be small. Our model can predict Cis-AKI early and may be helpful for its avoidance.</p>","PeriodicalId":50610,"journal":{"name":"Cts-Clinical and Translational Science","volume":"18 1","pages":""},"PeriodicalIF":3.1000,"publicationDate":"2025-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/cts.70115","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cts-Clinical and Translational Science","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cts.70115","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"MEDICINE, RESEARCH & EXPERIMENTAL","Score":null,"Total":0}
引用次数: 0

Abstract

Predicting cisplatin-induced acute kidney injury (Cis-AKI) before its onset is important. We aimed to develop a predictive model for Cis-AKI using patient clinical information based on an interpretable machine learning algorithm. This single-center retrospective study included hospitalized patients aged ≥ 18 years who received the first course of cisplatin chemotherapy from January 1, 2011, to December 31, 2020, at Nagoya City University Hospital. Cis-AKI-positive patients were defined using the serum creatinine criteria of the Kidney Disease Improving Global Outcomes guideline within 14 days of the last day of cisplatin administration in the first course. Patients who received cisplatin but did not develop AKI were considered negative. The CatBoost classification model was constructed with 29 explanatory variables, including laboratory values, concomitant medications, medical history, and cisplatin administration information. In total, 1253 patients were included, of whom 119 developed Cis-AKI (9.5%). The median time of AKI onset was 7 days, and the interquartile range was 5–8 days. The mean ± standard deviation of the total cisplatin dose in the initial treatment was 77.9 ± 27.1 mg/m2 in Cis-AKI-positive patients and 69.3 ± 22.6 mg/m2 in Cis-AKI-negative patients. The predictive performance was an ROC-AUC of 0.78. Model interpretation using SHapley Additive exPlanations showed that concomitant use of intravenous magnesium preparations was negatively correlated with Cis-AKI, whereas loop diuretics were positively correlated. This suggests the need for magnesium preparations to prevent AKI, although the effects of diuretics may be small. Our model can predict Cis-AKI early and may be helpful for its avoidance.

Abstract Image

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
利用可解释的机器学习模型和电子病历信息预测顺铂诱导的急性肾损伤
在顺铂引起的急性肾损伤(Cis-AKI)发病前预测是很重要的。我们的目标是基于可解释的机器学习算法,利用患者临床信息开发Cis-AKI的预测模型。这项单中心回顾性研究纳入了2011年1月1日至2020年12月31日在名古屋市立大学医院接受第一疗程顺铂化疗的年龄≥18岁的住院患者。顺铂阳性患者在第一个疗程中顺铂给药最后一天的14天内使用肾脏疾病改善全球结局指南的血清肌酐标准进行定义。接受顺铂治疗但未发生AKI的患者被认为是阴性。CatBoost分类模型由29个解释变量构建,包括实验室值、伴随用药、病史和顺铂给药信息。共纳入1253例患者,其中119例发展为Cis-AKI(9.5%)。AKI发病的中位时间为7天,四分位数间距为5 ~ 8天。顺- aki阳性患者初始顺铂总剂量的平均值±标准差为77.9±27.1 mg/m2,顺- aki阴性患者为69.3±22.6 mg/m2。预测性能的ROC-AUC为0.78。使用SHapley加性解释的模型解释显示,同时使用静脉镁制剂与顺式aki呈负相关,而环形利尿剂与顺式aki呈正相关。这表明需要镁制剂来预防AKI,尽管利尿剂的作用可能很小。我们的模型可以早期预测Cis-AKI,并可能有助于避免其发生。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
Cts-Clinical and Translational Science
Cts-Clinical and Translational Science 医学-医学:研究与实验
CiteScore
6.70
自引率
2.60%
发文量
234
审稿时长
6-12 weeks
期刊介绍: Clinical and Translational Science (CTS), an official journal of the American Society for Clinical Pharmacology and Therapeutics, highlights original translational medicine research that helps bridge laboratory discoveries with the diagnosis and treatment of human disease. Translational medicine is a multi-faceted discipline with a focus on translational therapeutics. In a broad sense, translational medicine bridges across the discovery, development, regulation, and utilization spectrum. Research may appear as Full Articles, Brief Reports, Commentaries, Phase Forwards (clinical trials), Reviews, or Tutorials. CTS also includes invited didactic content that covers the connections between clinical pharmacology and translational medicine. Best-in-class methodologies and best practices are also welcomed as Tutorials. These additional features provide context for research articles and facilitate understanding for a wide array of individuals interested in clinical and translational science. CTS welcomes high quality, scientifically sound, original manuscripts focused on clinical pharmacology and translational science, including animal, in vitro, in silico, and clinical studies supporting the breadth of drug discovery, development, regulation and clinical use of both traditional drugs and innovative modalities.
期刊最新文献
Inhibition of Tacrolimus Metabolism by Cannabidiol and Its Metabolites In Vitro A Randomized Hybrid-Effectiveness Trial Comparing Pharmacogenomics (PGx) to Standard Care: The PGx Applied to Chronic Pain Treatment in Primary Care (PGx-ACT) Trial AI In Action: Redefining Drug Discovery and Development Pharmacogenetic Information on Drug Labels of the Italian Agency of Medicines (AIFA): Actionability and Comparison Across Other Regulatory Agencies Pharmacokinetics of a Novel Piperaquine Dispersible Granules Formulation Under Fasting and Various Fed Conditions Versus Piperaquine Tablets When Fasted in Healthy Tanzanian Adults: A Randomized, Phase I Study
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1